Clinical trials: CVD - Cardiovascular Disease
Hereditary Angioedema
A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema
The goal of this clinical trial is to test the drug navenibart in participants with hereditary angioedema (HAE). One group of participants will get 1 dose of navenibart, and 2 other groups will get 2 doses of navenibart.
- Trial name
- NCT05695248
- Testing
- Navenibart
- Where
- 20 sites in United States, Bulgaria and 4 more
- Volunteers
- 29 people
- Sponsor
- Astria Therapeutics, Inc.
Subarachnoid Hemorrhage, Aneurysmal
Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH
Safety and Pharmacokinetic study comparing intracisternal EG-1962 to enternal nimopidine in the treatment of aneurysmal subarachnoid hemorrhage.
- Trial name
- NCT02893826
- Testing
- EG-1962 (nimodipine microparticles), Enteral Nimodipine
- Where
- 4 sites in United States, Canada
- Volunteers
- 6 people
- Sponsor
- Edge Therapeutics Inc
Essential Hypertension
Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension
This study is an exploratory Phase 1 randomized, double-blind (Investigator and study subject and 2-D echo endpoint assessor), placebo-controlled single IV infusion dose escalation study that will enroll up to approximately 32…
- Trial name
- NCT01873885
- Testing
- Experimental: Single IV Infusion Vasomera (PB1046)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Hypertension
Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone
This study will test the effectiveness and safety of a combination treatment in patients whose blood pressure is not controlled with a single medication.
- Trial name
- NCT00170989
- Testing
- valsartan plus hydrochlorothiazide
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 2,714 people
- Sponsor
- Novartis
Coronary Artery Disease, Heart Valve Diseases
Spectroscopic Assessment of Intramyocardial Oxygen Saturation Feasibility During Open-heart Surgery
This traditional feasibility study aims to capture preliminary safety and effectiveness information on a near-final Investigational Device design to adequately plan the forthcoming pivotal study.
- Trial name
- NCT05479968
- Testing
- Spectrocor device
- Where
- Finland
- Volunteers
- 15 people
- Sponsor
- Spectrocor
Atrial Fibrillation
REVEAL AF: Incidence of AF in High Risk Patients
This study is to determine, through continuous monitoring with the Reveal implantable cardiac monitor (ICM), the incidence of atrial fibrillation (AF) in patients suspected to be at high risk for having AF and to understand how…
- Trial name
- NCT01727297
- Testing
- REVEAL Implantable Cardiac Monitor
- Where
- 58 sites in United States, Austria and 5 more
- Volunteers
- 446 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Atrial Fibrillation
aMAZE Study: LAA Ligation Adjunctive to PVI for Persistent or Longstanding Persistent Atrial Fibrillation
This study is a prospective, multicenter, randomized (2:1) controlled study to evaluate the safety and effectiveness of the LARIAT System to percutaneously isolate and ligate the Left Atrial Appendage from the left atrium as an…
- Trial name
- aMAZE (NCT02513797)
- Testing
- LARIAT + PVI, Pulmonary Vein Isolation
- Where
- 53 sites in United States
- Volunteers
- 600 people
- Sponsor
- AtriCure, Inc.
Severe Aortic Stenosis
SOURCE XT REGISTRY
This registry is to expand upon existing data sets, to identify patient characteristics and indicators related to complications and clinical benefits for patients with symptomatic severe calcific degenerative aortic stenosis that…
- Trial name
- NCT01238497
- Testing
- TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
- Where
- 104 sites in Austria, Belgium and 16 more
- Volunteers
- 2,954 people
- Sponsor
- Edwards Lifesciences
Healthy Volunteers
Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam
The study is an open-label, fixed-sequence, cross-over study conducted at a single Clinical Unit to assess the pharmacokinetics (PK) of midazolam in healthy male and female (non-childbearing potential) subjects when administered…
- Trial name
- NCT05052710
- Testing
- AZD4831, Midazolam
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Atherosclerosis, Coronary Artery Disease
PLATINUM Diversity
To compile acute procedural performance and clinical outcomes data for the Promus PREMIER everolimus-eluting coronary stent system in understudied/underserved patient populations including women and minorities.
- Trial name
- NCT02240810
- Testing
- Percutaneous coronary intervention (Promus PREMIER)
- Where
- 52 sites in United States
- Volunteers
- 1,501 people
- Sponsor
- Boston Scientific Corporation
Growth Hormone Deficiency, Idiopathic Short Stature
Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.
- Conditions
- Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small for Gestational Age
- Trial name
- NCT04798690
- Where
- South Korea
- Volunteers
- 5,000 people
- Sponsor
- Dong-A ST Co., Ltd.
Low Cardiac Output
Efficacy, Safety of Hypertonic Lactate Soln. as Fluid Resuscitation Compared With Ringer's Lactate in Post-CABG Pats
Prospective, randomized, open-label study to assess the efficacy and safety of hypertonic lactate solution, compared to Ringer's Lactate as fluid resuscitation to maintain hemodynamic stability in post-coronary artery bypass…
- Trial name
- NCT00529490
- Testing
- Hypertonic lactate, Ringer's lactate
- Where
- Indonesia
- Volunteers
- 230 people
- Sponsor
- Innogene Kalbiotech Pte. Ltd
Severe Aortic Stenosis
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).
The purpose of the study is to investigate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with severe, symptomatic Aortic Stenosis (AS) at intermediate surgical risk by randomizing patients…
- Trial name
- SURTAVI (NCT01586910)
- Testing
- Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR), Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
- Where
- 86 sites in United States, Canada and 7 more
- Volunteers
- 1,746 people
- Sponsor
- Medtronic Cardiovascular
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies.
- Trial name
- KPT-IST-391 (NCT06225310)
- Testing
- Selinexor, Ruxolitinib, Methylprednisolone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oncotherapeutics
Essential Hypertension
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
This study was a non-interventional, secondary use of data, retrospective, cohort study, and the data to be extracted in this study was used as secondary use of collected patient information in the database (Japan Medical Data…
- Trial name
- NCT06604897
- Where
- United States
- Volunteers
- 1,405 people
- Sponsor
- Novartis Pharmaceuticals
Acute Ischemic Stroke
Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy
This is a randomized, double-blinded, placebo-controlled study investigating the safety and efficacy of QD202 injection in patients with acute ischemic stroke undergoing thrombolysis excluding endovascular thrombectomy.
- Trial name
- NCT07581210
- Testing
- QD202
- Where
- 14 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai QuietD Biotechnology Co., Ltd.
Hematological Malignancies
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
- Trial name
- MonumenTAL-1 (NCT04634552)
- Testing
- Talquetamab
- Where
- 78 sites in United States, Belgium and 9 more
- Volunteers
- 510 people
- Sponsor
- Janssen Research & Development, LLC
Acute Ischemic Stroke, Large Vessel Occlusion
Study on the Efficacy and Safety of T-02 for the Treatment for Acute Ischemic Stroke
To examine the revascularization efficacy and safety of T-02 and its associated performance characteristics in treatment of appropriately selected subjects experiencing an acute ischemic stroke when the treatment is initiated…
- Conditions
- Acute Ischemic Stroke, Large Vessel Occlusion, Vascular Occlusion, Thrombosis
- Trial name
- T-02 (NCT05342038)
- Testing
- T-02
- Sponsor
- Biomedical Solutions Inc.
Chronic Kidney Diseases, Inflammation
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
Patients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial.
- Trial name
- RESCUE (NCT03926117)
- Testing
- Ziltivekimab
- Where
- 49 sites in United States
- Volunteers
- 264 people
- Sponsor
- Novo Nordisk A/S
Tumors
Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours
The purpose of this study is to determine whether doses of 30 mg and 45 mg AZD2171 can be well tolerated without significant drug withdrawal when accompanied by a suitable hypertension management strategy or dose reduction.
- Trial name
- NCT00264004
- Testing
- AZD2171
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 119 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.